Second Hospital of Jilin University
吉林大学第二医院
Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Second Hospital of Jilin University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌0 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
- Hepatocellular carcinoma肝细胞癌15 papers led
- Stomach cancer胃癌17 papers led
- Lung cancer肺癌37 papers led
- Pancreatic cancer胰腺癌8 papers led
- Breast cancer乳腺癌20 papers led
- Glioma胶质瘤10 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤11 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤1 paper led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤4 papers led
- Lymphoma淋巴瘤6 papers led
- IgG4-related diseaseIgG4相关性疾病5 papers led
- Coronary heart disease冠心病12 papers led3 open trials led
- Congenital heart disease先天性心脏病2 papers led
- Scoliosis脊柱侧弯1 paper led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化7 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
- Pompe disease庞贝病1 paper led
- Behçet disease白塞病1 paper led
- Alport syndromeAlport 综合征0 papers led
- IgA nephropathyIgA 肾病7 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
Not listed for: Hepatoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led no English-language PubMed papers on nasopharyngeal carcinoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status2
Cancer
Hepatocellular carcinoma
肝细胞癌Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changchun for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07010588
Age 18 years to 75 years (registered criteria)
Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led15
- Prognostic evaluation of glycolysis markers in hepatocellular carcinoma: insights from meta-analysis and multi-omics approaches.
- Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma.
- New insights into combined immunotherapy for hepatocellular carcinoma associated with liver cirrhosis.
- FGA influences invasion and metastasis of hepatocellular carcinoma through the PI3K/AKT pathway.
- Long non-coding RNA LNC-POTEM-4 promotes HCC progression via the LNC-POTEM-4/miR-149-5p/Wnt4 signaling axis.
- The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity.
- Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma.
- Precision diagnosis of hepatocellular carcinoma.
- Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications.
- Rap_GAP Domain of TSC2 Contributes to Tumor Suppression Through mTOR Signaling in Human Hepatocellular Carcinoma.
- LncRNA SNHG14 Sponges miR-206 to Affect Proliferation, Apoptosis, and Metastasis of Hepatocellular Carcinoma Cells by Regulating SOX9.
- Endoplasmic reticulum stress: Multiple regulatory roles in hepatocellular carcinoma.
- Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma.
- Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
- Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Stomach cancer
胃癌Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for stomach cancer211 hospitals in China for stomach cancer
No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led17
- Molecular targets and mechanisms of traditional Chinese medicine combined with chemotherapy for gastric cancer: a meta-analysis and multi-omics approach.
- An artificial intelligence model utilizing endoscopic ultrasonography for differentiating small and micro gastric stromal tumors from gastric leiomyomas.
- The mechanism study of LncRNA AC012181.2 targeting HERPUD1 protein in regulating stromal stem cells participating in metabolic reprogramming for gastric cancer metastasis.
- Rac1 in gastric cancer: a molecular driver of invasion, EMT, and therapeutic resistance.
- SLC39A5 promotes the malignant progression of gastric cancer by activating BATF phosphorylation.
- Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
- Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
- Genome-wide investigation of lncRNAs revealed their tight association with gastric cancer.
- Prognostic significance of an innovative staging system based on the logarithmic odds of positive lymph nodes for resectable gastroesophageal cancer after neoadjuvant chemoradiation: a population-based study with external validation of data
- Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan.
- A case of gastric granulosa cell tumor resected by endoscopic submucosal dissection.
- MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.
- Podoplanin promotes the carcinogenicity of gastric cancer by activating ezrin and mediating the crosstalk between tumour cells and cancer-associated fibroblasts.
- Gastric adenocarcinoma with germ cell tumor components: a rare case report.
- CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration.
- Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study.
- Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review.
Cancer
Lung cancer
肺癌Led 37 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for lung cancer251 hospitals in China for lung cancer
No open trial on lung cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led37
- Engineering ferroptosis radiosensitizer for SPARC-targeted degradation: A strategy to reverse radioresistant non-small cell lung cancer.
- Epigenetic modulation of cisplatin sensitivity by the M6A-linked ceRNA network in non-small cell lung cancer.
- Super-Resolution Fluorescence Imaging Reveals the Mechanism of NRP1 Clustering on Non-Small-Cell Lung Cancer Membranes.
- Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient.
- Cinobufagin Enhances the Sensitivity of Cisplatin-Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways.
- Super-resolution imaging reveals the role of DDR1 cluster in NSCLC proliferation.
- Multiple primary colonic carcinomas with lung small-cell neuroendocrine carcinoma: A case report.
- Biomarkers of peripheral blood neutrophil extracellular traps in the diagnosis and progression of malignant tumors.
- The impact of LncRNA-SOX2-OT/let-7c-3p/SKP2 Axis on head and neck squamous cell carcinoma progression: Insights from bioinformatics analysis and experimental validation.
- The diagnosis and management of multiple ground-glass nodules in the lung.
- Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
- Bronchial artery pseudoaneurysm presenting with hemoptysis and hemothorax after pulmonary lobectomy: a case report and literature review.
- Epithelioid trophoblastic tumor with lung metastasis: A case report and literature review.
- Pulmonary sarcomatoid carcinoma: A rare case report, diagnostic dilemma and review of literature.
- Porphyrin Cholesterol Conjugates for Enhanced Photodynamic Immunotherapy toward Lung Cancer.
- LncRNA FAM138B inhibits the progression of non-small cell lung cancer through miR-105-5p.
- Concordance of ctDNA and tissue mutations in NSCLC: A meta-analysis.
- Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era.
- Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.
- Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
- Spontaneous histological transformation of lung squamous-cell carcinoma to large cell neuroendocrine carcinoma and small cell lung cancer.
- RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
- CAPZA1 is low expressed in non-small cell lung cancer and contributed to tumor cell proliferation and metastasis.
- Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression.
- Long non-coding MELTF Antisense RNA 1 promotes and prognosis the progression of non-small cell lung cancer by targeting miR-1299.
- MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.
- Prediction of the Invasiveness of Ground-Glass Nodules in Lung Adenocarcinoma by Radiomics Analysis Using High-Resolution Computed Tomography Imaging.
- Human umbilical vein endothelial cells-derived microRNA-203-containing extracellular vesicles alleviate non-small-cell lung cancer progression through modulating the DTL/p21 axis.
- Circular RNA circTTBK2 facilitates non-small-cell lung cancer malignancy through the miR-873-5p/TEAD1/DERL1 axis.
- A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.
- The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
- Ubiquitin C-terminal hydrolase-L1 expression in non-small-cell lung cancer and its association with clinicopathological features and prognosis.
- Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: a retrospective study.
- Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
- HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.
- LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p.
- Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status3
- A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Cancer
Pancreatic cancer
胰腺癌Led 8 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for pancreatic cancer192 hospitals in China for pancreatic cancer
No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Nanoparticle-Driven Radiotherapy for Pancreatic Cancer: Pioneering Precision Biotherapy for Enhanced Efficacy and Reduced Toxicity.
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.
- Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer.
- Breast cancer with pancreatic metastasis:A case report.
- FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
- Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer.
- Repression of circRNA_000684 inhibits malignant phenotypes of pancreatic ductal adenocarcinoma cells via miR-145-mediated KLF5.
- Screening and Validation of Independent Predictors of Poor Survival in Pancreatic Cancer.
Cancer
Breast cancer
乳腺癌Led 20 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changchun for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05744687
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan
- RecruitingAlbumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-07
- Posted
- Registry
- NCT04136782
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingSj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- Phase
- Not given
- Started
- 2021-07
- Posted
- Registry
- NCT04476485
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led20
- Near-infrared fluorescent probe for selective detection of nitroreductase and tumor imaging in breast cancer.
- Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine-Mediated Radiosensitization for Triple-Negative Breast Cancer Therapy.
- "All-in-one" nano-system for smart delivery and imaging-guided combination therapy of triple-negative breast cancer.
- Enhanced value of chest computed tomography radiomics features in breast density classification.
- Targeting of the IL-33/Wnt axis restricts breast cancer stemness and metastasis.
- Injectable Nano-in-Gel Vaccine for Spatial and Temporal Control of Vaccine Kinetics and Breast Cancer Postsurgical Therapy.
- Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain.
- Elucidating the nature of acinic cell carcinoma of the breast with high-grade morphology: evidence from case report.
- Non-coding RNAs mediated inflammation in breast cancers.
- Breast cancer with pancreatic metastasis:A case report.
- First diagnosed invasive lobular carcinoma of the breast combined with gastric metastasis and bone metastasis: a case report and review of the literature.
- Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers.
- Atrazine promotes breast cancer development by suppressing immune function and upregulating MMP expression.
- MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target.
- Prognostic value of the preoperative prognostic nutritional index and systemic immuno-inflammatory index in Chinese breast cancer patients: A clinical retrospective cohort study.
- lncRNA GAS5 Sensitizes Breast Cancer Cells to Ionizing Radiation by Inhibiting DNA Repair.
- Breast Cancer Screening Practices and Satisfaction With Healthcare Providers in Chinese Women: A Cross-sectional Study.
- Identification of a novel lncRNA-miRNA-mRNA competing endogenous RNA network associated with prognosis of breast cancer.
- TTK predicts triple positive breast cancer prognosis and regulates tumor proliferation and invasion.
- Combining bioinformatics analysis and experiments to explore CARNS1 as a prognostic biomarker for breast cancer.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status13
- Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
- Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
Cancer
Glioma
胶质瘤Led 10 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led10
- PDGF-D Promotes Epithelial-Mesenchymal Transition of Glioma Cells Through the NF-κB/NOTCH1 Pathway.
- Identification of the high-risk population facing early death in older patients with primary intracranial glioma: a retrospective cohort study.
- Nano-Drug Delivery Systems Targeting MMPs: A Promising Treatment for Gliomas.
- Balanced transformer: efficient classification of glioblastoma and primary central nervous system lymphoma.
- The epithelial-mesenchymal transition of glioma cells promotes tissue factor expression via the miR200a/ZEB1 axis.
- A review on the role of different ephrins in glioma.
- Cyclophilin A contributes to shikonin-induced glioma cell necroptosis and promotion of chromatinolysis.
- Nitidine chloride suppresses epithelial-mesenchymal transition and stem cell-like properties in glioblastoma by regulating JAK2/STAT3 signaling.
- Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review.
- Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy.
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 11 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led11
- Targeting mechanotransduction in osteosarcoma.
- Anti-osteosarcoma activity of Corynoline via Src/JNK signaling-mediated cell cycle arrest and mitochondrial apoptosis.
- Primary extraskeletal osteosarcoma of rectal mesentery: a rare case and literature review.
- Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
- The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis.
- Development of nomogram and discussion of radiotherapy effect for osteosarcoma survival.
- Silencing of circ-CDK14 suppresses osteosarcoma progression through the miR-198/E2F2 axis.
- Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
- EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.
- Circ_0001174 facilitates osteosarcoma cell proliferation, migration, and invasion by targeting the miR-186-5p/MACC1 axis.
- Circular RNA hsa_circ_0069117 suppresses proliferation and migration of osteosarcoma cells lines via miR-875-3p/PF4V1 axis.
Earlier papers (2016–2020)29
- Construction of an integrated human osteosarcoma database, HOsDb, based on literature mining, microarray analysis, and database retrieval.
- Long non-coding RNA DSCAM-AS1 upregulates USP47 expression through sponging miR-101-3p to accelerate osteosarcoma progression.
- TUSC8 inhibits the development of osteosarcoma by sponging miR‑197‑3p and targeting EHD2.
- LncRNA MALAT1 facilitates lung metastasis of osteosarcomas through miR-202 sponging.
- Integrated bioinformatics analysis of miRNA expression in Ewing sarcoma and potential regulatory effects of miR-21 via targeting ALCAM/CD166.
- Potential Regulatory Effects of miR-182-3p in Osteosarcoma via Targeting EBF2.
- Overexpression of carboxypeptidase X M14 family member 2 predicts an unfavorable prognosis and promotes proliferation and migration of osteosarcoma.
- Down-regulation of microRNA-31-5p inhibits proliferation and invasion of osteosarcoma cells through Wnt/β-catenin signaling pathway by enhancing AXIN1.
- Down-regulation of RAC2 by small interfering RNA restrains the progression of osteosarcoma by suppressing the Wnt signaling pathway.
- Identification of biomarkers associated with the recurrence of osteosarcoma using ceRNA regulatory network analysis.
- MicroRNA-377 exerts a potent suppressive role in osteosarcoma through the involvement of the histone acetyltransferase 1-mediated Wnt axis.
- RNA Sequencing of Osteosarcoma Gene Expression Profile Revealed that miR-214-3p Facilitates Osteosarcoma Cell Proliferation via Targeting Ubiquinol-Cytochrome c Reductase Core Protein 1 (UQCRC1).
- Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling.
- Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma.
- Long noncoding RNA LSINCT5 acts as an oncogene via increasing EZH2-induced inhibition of APC expression in osteosarcoma.
- Reduced expression of miR-564 is associated with worse prognosis in patients with osteosarcoma.
- MicroRNA-1270 is associated with poor prognosis and its inhibition yielded anticancer mechanisms in human osteosarcoma.
- Cytotoxic ring A-seco triterpenoids from the stem bark of Dysoxylum lukii.
- JTC-801 exerts anti-proliferative effects in human osteosarcoma cells by inducing apoptosis.
- Emerging Roles of Circular RNAs in Osteosarcoma.
- MicroRNA-152 inhibits cell proliferation of osteosarcoma by directly targeting Wnt/β-catenin signaling pathway in a DKK1-dependent manner.
- MicroRNA-381 suppresses the proliferation of osteosarcoma cells through LRH-1/Wnt/β-catenin signaling pathway.
- Downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression.
- Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma.
- Investigation of crucial genes and microRNAs in conventional osteosarcoma using gene expression profiling analysis.
- Overexpression of microRNA-448 inhibits osteosarcoma cell proliferation and invasion through targeting of astrocyte elevated gene-1.
- Vitamin K4 inhibits the proliferation and induces apoptosis of U2OS osteosarcoma cells via mitochondrial dysfunction.
- Overexpression of microRNA-495 suppresses the proliferation and invasion and induces the apoptosis of osteosarcoma cells by targeting high-mobility group nucleosome-binding domain 5.
- Contribution of the GSTP1 gene polymorphism to the development of osteosarcoma in a Chinese population.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Changchun for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
- Giant gastrointestinal stromal tumor with predominantly cystic changes: a case report and literature review.
- Transdifferentiation of pancreatic stromal tumor into leiomyosarcoma with metastases to liver and peritoneum: a case report.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for multiple myeloma175 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Intratumor microbiota: Occult participants in the microenvironment of multiple myeloma.
- Recent advance of small-molecule drugs for clinical treatment of multiple myeloma.
- Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study.
- Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a.
Blood disorders
Lymphoma
淋巴瘤Led 6 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for lymphoma199 hospitals in China for lymphoma
No open trial on lymphoma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led6
- Perilesional dominance: radiomics of multiparametric MRI enhances differentiation of IgG4-Related ophthalmic disease and orbital MALT lymphoma.
- A case of primary lymphoma of the right atrium was misdiagnosed by ultrasound.
- Expression of senescence-related CD161 promotes extranodal NK/T cell lymphoma by affecting T cell phenotype and cell cycle.
- Balanced transformer: efficient classification of glioblastoma and primary central nervous system lymphoma.
- To Explore MR Imaging Radiomics for the Differentiation of Orbital Lymphoma and IgG4-Related Ophthalmic Disease.
- Diagnostic Challenge of Sarcomatoid Variant of ALK-Positive Anaplastic Large Cell Lymphoma: Case Report and Updated Systematic Literature Review.
Chinese-language papers (not in the count)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 5 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Changchun for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- Perilesional dominance: radiomics of multiparametric MRI enhances differentiation of IgG4-Related ophthalmic disease and orbital MALT lymphoma.
- Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link.
- A comprehensive review of IgG4-related pancreatitis: pathogenesis, diagnosis, and therapeutic advances.
- An overlap of IgG4-related tubulointerstitial nephritis and microscopic polyangiitis-associated glomerulonephritis: a case-based review.
- To Explore MR Imaging Radiomics for the Differentiation of Orbital Lymphoma and IgG4-Related Ophthalmic Disease.
Other diseases
Coronary heart disease
冠心病Led 12 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.
5 hospitals in Changchun for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingTicagrelor-Based Dual Antiplatelet Therapy Duration in CABG
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT06981390
Age 18 years to 80 years (registered criteria)
Led by Second Hospital of Jilin UniversityChangchun
- Not yet recruitingTotal Arterial vs. Mixed Grafting in Left Coronary CABG
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07057713
Age 18 years to 80 years (registered criteria)
Led by Second Hospital of Jilin UniversityChangchun
- Not yet recruitingPerioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07650487
Age 21 years to 80 years (registered criteria)
Led by Second Hospital of Jilin UniversityChangchun
- RecruitingEfficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07110415
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai
- Not yet recruitingOptimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phase
- N/A
- Started
- 2021-09
- Posted
- Registry
- NCT04995159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Prediction and Risk Factor Analysis of in-Stent Restenosis and Revascularization after Coronary Stenting Based on Machine Learning.
- Association between leukocyte-derived composite indices and premature coronary artery disease: a cross-sectional study.
- Plasma microRNA-210 is associated with VEGF-A and EphrinA3 and relates to coronary collateral circulation in patients with coronary heart disease: a cross-sectional study.
- RIMA-SVG versus Ao-SVG in coronary artery bypass grafting: protocol for a prospective, randomised, double-blind, non-inferiority and single-centre trial.
- Unraveling the immune activation mechanisms of DAMPs in coronary artery disease through transcriptomic and single-cell analyses.
- The association between the triglyceride-glucose index and in-stent restenosis in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
- Correlation of circulating fibroblast growth factor 21 levels with inflammatory factors and the degree of coronary artery stenosis in patients with acute myocardial infarction.
- The recent advances in cell delivery approaches, biochemical and engineering procedures of cell therapy applied to coronary heart disease.
- Association between the triglyceride-glucose index and left ventricular global longitudinal strain in patients with coronary heart disease in Jilin Province, China: a cross-sectional study.
- Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis.
- Deep Learning Model for Coronary Angiography.
- Abnormal expression of TGFBR2, EGF, LRP10, and IQGAP1 is involved in the pathogenesis of coronary artery disease.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status25
- Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study
- Total Arterial vs. Mixed Grafting in Left Coronary CABG
- Comparison of RIMA-SVG and Ao-SVG Techniques in Coronary Artery Bypass Grafting
- Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
- Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
- Drug-coated Balloon Versus Drug-eluting Stent for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phitys I™ Percutaneous Left Ventricular Assist System Study
- Phimume® Percutaneous Left Ventricular Assist System Study
- Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus
- CT Myocardial Perfusion to Guide the Diagnosis and Treatment of Patients With Stable Coronary Artery Disease (POTENTIAL)
- A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease
- The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
- Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
- PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System
- XIENCE 28 USA Study
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- XIENCE 28 Global Study
- The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
- Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
- Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults
- Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
- Acarbose Cardiovascular Evaluation Trial
Other diseases
Congenital heart disease
先天性心脏病Led 2 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.08%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Changchun for congenital heart disease207 hospitals in China for congenital heart disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07292896
Age 18 years to 79 years (registered criteria)
Led by First Hospital of China Medical University; 11 listed hospitals as study sitesBeijing, Changchun, Chengdu, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Other diseases
Scoliosis
脊柱侧弯Led 1 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for scoliosis107 hospitals in China for scoliosis
No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 7 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changchun for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Identification and validation of biomarkers related to ferroptosis in idiopathic pulmonary fibrosis.
- Higher body mass index was associated with a lower mortality of idiopathic pulmonary fibrosis: a meta-analysis.
- Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
- Prognostic significance of peripheral blood S100A12, S100A8, and S100A9 concentrations in idiopathic pulmonary fibrosis.
- The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review.
- Genomic Fingerprint Associated with Familial Idiopathic Pulmonary Fibrosis: A Review.
- Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status3
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changchun for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement-coagulation cascade and NF-ĸB signaling in SOD1G93A mice.
- Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation.
Other diseases
Pompe disease
庞贝病Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Changchun for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Changchun for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Changchun for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07390123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- External validation of the updated international IgA nephropathy prediction tool in a Chinese population.
- Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report.
- Role of telitacicept in the treatment of IgA nephropathy.
- Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review.
- Urinary exosomal circular RNAs of sex chromosome origin are associated with gender-related risk differences of clinicopathological features in patients with IgA nephropathy.
- Differential expression analysis of urinary exosomal circular RNAs in patients with IgA nephropathy.
- Clinical and pathological analysis of renal biopsies of elderly patients in Northeast China: a single-center study.
Earlier papers (2016–2020)4
- Clinical and Pathological Analysis of 4910 Patients Who Received Renal Biopsies at a Single Center in Northeast China.
- Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China.
- Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.
- Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis.
All its trials on ClinicalTrials.gov, any status4
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changchun for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
吉林大学第二医院
Second Hospital of Jilin University
长春
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.
Second hospital of Jilin University; Eye Center in the Second Hospital of Jilin University; Second Hospital of Jilin Unersity